Durham, North Carolina, June 1, 2007- Thrombotargets Corp., a privately owned biotech company focused on the development of new drug candidates and technologies on the field of hemostasia, today announced the membership of its new Scientific Advisory Board. The Scientific Advisory Board members have been selected for their expertise on hemostasia, especially by their knowledge of vascular biology, coagulation diseases management, and dental procedure treatment of coagulation disease patients.
